Applying a Phase II Futility Study Design to Therapeutic Stroke Trials-Reference-Cited by-同舟云学术

Applying a Phase II Futility Study Design to Therapeutic Stroke Trials

Published:2005-11 Issue:11 Volume:36 Page:2410-2414
ISSN:0039-2499
Container-title:Stroke
language:en
Short-container-title:Stroke

Author:

Palesch Yuko Y.¹,Tilley Barbara C.¹,Sackett David L.¹,Johnston Karen C.¹,Woolson Robert¹

Affiliation:

1. From the Department of Biostatistics, Bioinformatics & Epidemiology (Y.Y.P., B.C.T., R.W.), Medical University of South Carolina, Charleston, SC; Trout Centre at Irish Lake (D.L.S.), Canada; and the Department of Neurology and Health Evaluation Sciences (K.C.J.), University of Virginia.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Advanced and Specialized Nursing,Cardiology and Cardiovascular Medicine,Neurology (clinical)

Reference18 articles.

1. WHY DO NEUROPROTECTIVE DRUGS WORK IN ANIMALS BUT NOT HUMANS?

2. Planned versus attained design in phase II clinical trials

3. Herson J. Statistical aspects in the design and analysis of Phase II clinical trials. In: Buyse ME Staquet MJ Sylvester RJ eds. Cancer Clinical Trials: Methods and Practice. Oxford: Oxford University Press; 1984.

4. Predictive Probability Early Termination Plans For Phase II Clinical Trials

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interpreting a Bayesian phase II futility clinical trial;Trials;2022-11-22

2. Futility Designs;Principles and Practice of Clinical Trials;2022

3. Design of Stroke-Related Clinical Trials;Stroke;2022

4. Clinical Scales to Assess Patients With Stroke;Stroke;2022

5. Lessons Learned from Phase II and Phase III Trials Investigating Therapeutic Agents for Cerebral Ischemia Associated with Aneurysmal Subarachnoid Hemorrhage;Neurocritical Care;2021-12-23